Followers | 91 |
Posts | 3296 |
Boards Moderated | 0 |
Alias Born | 10/18/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 11, 2020 2:29:33 AM
Investors should know that Moderna's scientific approach to vaccine development is unproven. But its mature technology platform and long-standing collaborations with government institutions and established pharmaceutical companies mean it's well-positioned to thrive in the long-term whether or not its COVID-19 vaccine pans out as hoped.
Moderna was an exciting company before COVID-19
Moderna's technology platform is centered around its ability to quickly produce clinical trial-ready sequences of genetic information. This genetic information is the active ingredient in all of Moderna's products. Then, using the company's patented therapeutic delivery platform, the sequence infiltrates its cellular targets and prompts them to react in the way Moderna envisions.
Unlike similar technologies for drug delivery, Moderna's tech platform is highly reliable and safe at transporting its payload into cells. This means that the company has already overcome a significant scientific and engineering hurdle that its competitors have not. In a nutshell, it also means that the company has a solution in hand and is searching for the right disease problem to solve. There's no guarantee that Moderna will produce a COVID-19 vaccine successfully, but the marginal cost of the attempt will be low either way.
A strand of DNA
IMAGE SOURCE: GETTY IMAGES.
The same goes for a handful of other diseases that Moderna could consider targeting. By investing so much in its technology platform, Moderna has driven down the cost of pipeline gambles to the point where the company's own literature compares it to running a software program. In other words, Moderna has a dominating strategic advantage among biotechs because it is extremely resilient against pipeline risks.
Moderna's clinical collaborations bolster its chances of success
Moderna has several scientific peers in the COVID-19 vaccine space. However, Moderna has an extensive number of collaborations that strengthened its competitive position long before the pandemic. Merck (NYSE:MRK), AstraZeneca (NYSE:AZN), Lonza (OTC:LZAGY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are partners in a handful of different Moderna therapeutic development efforts. In particular, Moderna's 2015 collaboration with Merck pertains directly to developing vaccines for infectious diseases using Moderna's technology platform and Merck's clinical trial expertise. These collaborations ensure that its candidate therapies and candidate vaccines have momentum in the clinical trial process right out of the gate.
Industry partnerships are only half of Moderna's collaboration story. Since 2013, Moderna has also partnered with government institutions like the Defense Advanced Research Projects Agency (DARPA) and later the Biomedical Advanced Research and Development Authority (BARDA) for its COVID-19 efforts.
Many of Moderna's peer companies are flush with collaborations in industry, but few have the same level of experience or comfort when dealing with government groups. The company's mixture of long-lasting and high-powered collaborations means that its vaccine development efforts get cash infusions upfront and critical sets of helping hands during the clinical trial process, increasing the chances of success.
Recent MRNA News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 11:05:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:08:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2024 03:44:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:34:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2024 07:28:01 PM
- Apple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More News • IH Market News • 07/03/2024 10:59:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 04:45:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:05:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 07:16:06 PM
- Apple Showcases AI at WWDC 2024, Nvidia Stock Split Starts Today, and More News • IH Market News • 06/10/2024 11:29:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:27:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:20:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:12:54 PM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:36:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:20:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:11:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:36:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:27:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 08:16:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 08:12:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:22:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:20:31 PM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM